{"entity":{"id":"nct06635785","kind":"trial","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AI-081 in advanced solid tumours, run by OncoC4, Inc., now recruiting.","summary":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06635785 by OncoC4, Inc., with 387 participants planned, started 2025-03-26 and due to reach its primary completion in 2027-06-30. Interventions recorded: AI-081.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06635785","url":"https://clinicaltrials.gov/study/NCT06635785"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ai-081"],"companies":["oncoc4"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06635785","phase":"1/2","setting":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","sponsor":"OncoC4, Inc.","enrolled":387,"outcomes":[]},"route":"/trials/nct06635785/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ai-081","kind":"drug","name":"AI-081","route":"/drugs/ai-081/"}],"company":[{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/"}]}}